A French venture capital firm that has an additional office in the USA is actively seeking investment opportunities within life sciences and healthcare sectors, with a focus on early stage. Initial investments can range from $100K – 3M, and largely varies by deal. The firm typically invests in the form of equity, and may take less equity in exchange for preemptive or pro-rata rights. The firm will consider global opportunities but focuses on USA and Europe-based companies.
The firm is interested in various opportunities within therapeutics, devices, diagnostics, and digital health. In therapeutics, the firm is excited about platform technologies (especially in oncology), DNA repair, and novel drug delivery mechanisms. Within devices, technologies that integrate or combine new technologies such as robotics, smart devices, IoT, and imaging are areas of interest. In diagnostics, point of care diagnostics technologies that can substantially transform the current standard of care are of interest. Lastly, within digital health, the firm is interested in telehealth, novel digital interventions, and any technology that successfully leverages AI to improve patient outcomes and clinical workflow. The firm is mostly stage and indication agnostic but tend to stray away from cardiovascular and CNS indications.
The firm has no specific company or management team requirements. The firm seeks to be a very active, hands-on investor and can support their portfolio companies on their operations, scalability, regulatory strategy, and more. The firm has a growing advisory board that companies can seek to leverage. The firm can act as either a lead or co-investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
The FDA’s Center for Devices and Radiological Health (aka CDRH aka the folks who approve med devices) had firings a little more than a week ago, continuing from the layoffs at the NIH and CDC. Early signs indicate a reduction of 10% – 15%. Those who lost their jobs included those funded by medical device user fees and not tax-payer dollars. Since the cuts affected probationary employees the most, recent hires to evaluate newer technologies like AI-assisted imaging and digital health are gone, making it hard to imagine approvals for these modalities would not grind to a halt. AdvaMed’s head, Scott Whitaker, conveyed that AdvaMed had sent a letter to HHS in response, emphasizing the importance of AI and related technologies, the patient-facing effects throwing a wrench in the approval machine would have, and the lack of tax-payer savings. This may have been effective, as in breaking news today, the Associated Press reported that some of the fired individuals received calls and messages reversing their dismissals, stating terminations were “rescinded effective immediately.”
Next Phase Newsletter 